Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

IIOVANCE BIOTHERAPEUTICS, INC.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
I

IOVANCE BIOTHERAPEUTICS, INC.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • History
  • Insider Transactions
Loading financials
Income statement waterfall. Revenue $99.31M. Net result −$47.32M. A thin axis line marks the loss-zone boundary.

Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.

  • Revenue: $99.31M. Running result $99.31M. Amtagvi: $90.72M. Proleukin: $8.59M.
  • Cost of revenue: −$43.6M. Running result $55.72M.
  • Gross profit: $55.72M. Running result $55.72M.
  • Operating costs: −$107.62M. Running result −$51.91M.
  • Operating income: −$51.91M. Running result −$51.91M.
  • Other income: $3.22M. Running result −$48.69M.
  • Pre-tax loss: −$48.69M. Running result −$48.69M.
  • Income tax benefit: $1.37M. Running result −$47.32M.
  • Net loss: −$47.32M. Running result −$47.32M.